Celldex Therapeutics, Inc. balance sheet CLDX

Annual Quarterly

As of Sep 30, 2026, Celldex Therapeutics, Inc. had total assets of $721.5 million and total liabilities of $72.1 million. Total assets were up 11.3% from a year earlier. Stockholders' equity was $649.5 million. It held $650.3 million in cash and investments against $9.9 million of total debt, net cash of $640.4 million. The current ratio, current assets divided by current liabilities, was 10.97.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the same quarter a year earlier.

Line	Q3 FY2026 Sep 30, 2026	Q2 FY2026 Jun 30, 2026	Q1 FY2026 Mar 31, 2026	Q4 FY2025 Dec 31, 2025	Q3 FY2025 Sep 30, 2025	Q2 FY2025 Jun 30, 2025	Q1 FY2025 Mar 31, 2025	Q4 FY2024 Dec 31, 2024
Assets
Cash	27 -25.2%	47 +105.9%	36 +108.5%	29 +1.8%	36 -1.0%	23 -46.1%	17 -85.1%	28 -18.6%
Short-term investments	623 +13.9%	670 +10.3%	416 -36.6%	490 -29.7%	547 -24.0%	607 -20.0%	656 -7.4%	697 +79.3%
Cash and investments	650 +11.5%	718 +13.8%	451 -32.9%	519 -28.5%	583 -22.9%	630 -21.4%	673 -18.3%	725 +71.2%
Total current assets	664 +9.8%	725 +11.8%	459 -33.8%	535 -28.4%	604 -22.4%	648 -20.1%	694 -16.9%	747 +73.1%
Property and equipment, net	11 +127.7%	10 +122.1%	7 +60.7%	5 +22.7%	5 +14.2%	4 +13.7%	5 +13.3%	4 +7.0%
Total assets	722 +11.3%	782 +13.0%	511 -30.9%	583 -26.4%	648 -21.2%	692 -18.1%	739 -14.9%	792 +70.2%
Liabilities and equity
Accounts payable	11 +163.4%	15 +607.9%	10 +203.8%	1 -63.9%	4 +283.0%	2 -45.5%	3 +5.4%	3 -6.6%
Total current liabilities	61 +30.2%	61 +86.0%	51 +60.8%	51 +29.1%	46 +44.8%	33 +19.2%	32 +21.8%	40 +26.9%
Total liabilities	72 +43.9%	68 +83.2%	55 +50.8%	56 +23.1%	50 +34.3%	37 +15.9%	36 +20.7%	45 +24.4%
Stockholders' equity	649 +8.5%	715 +9.0%	456 -35.1%	527 -29.4%	598 -23.9%	655 -19.4%	703 -16.2%	747 +74.1%
Debt
Lease liabilities	10 +276.6%	5 +61.8%	2 -44.3%	2 -38.7%	3 -15.1%	3 +27.1%	3 +62.2%	4 +50.0%
Total debt	10 +276.6%	5 +61.8%	2 -44.3%	2 -38.7%	3 -15.1%	3 +27.1%	3 +62.2%	4 +50.0%
Net cash	640 +10.3%	713 +13.6%	450 -32.9%	516 -28.4%	581 -22.9%	627 -21.6%	670 -18.5%	721 +71.3%
Ratios
Current ratio	10.97x	11.82x	8.92x	10.49x	13.01x	19.67x	21.67x	18.91x
Debt to equity	0.02x	0.01x	0.00x	0.00x	0.00x	0.00x	0.00x	0.01x
Return on equity	-47.59%	-42.06%	—	-49.08%	—	—	—	—
Return on assets	-42.83%	-38.42%	—	-44.38%	—	—	—	—
Book value per share	8.27	9.10	6.85	7.92	9.01	9.87	10.59	11.25

How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. More on our methodology.

Company profile

Industry: In Vitro & In Vivo Diagnostic Substances (SIC 2835)
Listed as: CLDX (Nasdaq)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: Hampton, NJ
SEC filer status: Large accelerated filer
SEC CIK: 744218
Former names: AVANT IMMUNOTHERAPEUTICS INC (until Sep 29, 2008); T CELL SCIENCES INC (until Aug 21, 1998)

Other In Vitro & In Vivo Diagnostic Substances companies

All 21 In Vitro & In Vivo Diagnostic Substances companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.